cust.co / Companies / OptimizeRx (OPRX)

OptimizeRx NRR

Net Revenue Retention history for OptimizeRx (OPRX) - Healthcare SaaS, Public stage. Sourced from SEC filings and earnings releases.

Latest NRR · FY2025-Q4
116.0%
All-time peak
127.0%
FY2023-Q3
All-time low
114.0%
FY2025-Q1
Disclosures tracked
11
since FY2023-Q3
QoQ flat
YoY ▲ 2.0pp

NRR vs GRR over time

0%37%73%110%146% FY2023-Q3FY2024-Q2FY-2024FY2025-Q1FY2025-Q3FY2025-Q4 Retention NRR (incl. expansion) GRR (excl. expansion) NRR — FY2023-Q3: 127% NRR — FY2023-Q4: 121% NRR — FY2024-Q2: 124% NRR — FY2024-Q3: 127% NRR — FY-2024: 121% NRR — FY2024-Q4: 121% NRR — FY2025-Q1: 114% NRR — FY2025-Q2: 121% NRR — FY2025-Q3: 120% NRR — FY-2025: 116% NRR — FY2025-Q4: 116% GRR — FY2023-Q3: 0% GRR — FY2023-Q4: 0% GRR — FY2024-Q2: 0% GRR — FY2024-Q3: 0% GRR — FY-2024: 0% GRR — FY2024-Q4: 0% GRR — FY2025-Q1: 0% GRR — FY2025-Q2: 0% GRR — FY2025-Q3: 0% GRR — FY-2025: 0% GRR — FY2025-Q4: 0%

Gross Retention excludes expansion - it shows pure churn / contraction loss. The gap between NRR and GRR is the expansion lift.

Peak NRR of 127.0% in FY2023-Q3. Latest is 116.0% - that's -11.0pp from peak.

OptimizeRx is above the Healthcare SaaS Public median by +7.5pp (cell median: 109%)

What the data shows

OptimizeRx (OPRX) is a healthcare saas company at the public stage. As of its most recent disclosure (FY2025-Q4), OptimizeRx reported a Net Revenue Retention rate of 116.0% - a strong result for B2B SaaS at this segment.

OptimizeRx's NRR peaked at 127.0% in FY2023-Q3, 11pp above today's level.

Within its peer set (healthcare saas companies at public stage in the $100k-$500k acv band), OptimizeRx's NRR is above the cell median of 109%. Compare against the full peer cell aggregate for distribution and top performers.

Customer mix

Total customers
Over $100K ARR
Over $1M ARR
US revenue mix
Top-10 concentration
Average ACV
$2,800,000
2025-12-31

Commercial structure

Contract shape and forward-booked revenue.

Multi-year contracts
Avg contract length
RPO (total)
cRPO (next 12mo)
New customers added
Subscription rev mix
30%
2024-12-31

Scale & headcount

Revenue, ARR, and team-size denominators for the productivity ratios.

Revenue (period)
$92M
2024-12-31
Total ARR
ARR growth (YoY)
AE headcount
Total employees

The post-sales motion

Pricing model
hybrid
Renewal cadence
annual
CS team size
Customers per CSM

Support tiers: Cadillac support · mid-tier support

CS team segments: Top 20 Pharma · Mid-tier pharma · Small-cap companies

What OptimizeRx is doing

Named CS initiatives across recent disclosures (newest first).

What they're working through

Challenges acknowledged by management. Useful peer signals — your team is probably not alone.

What execs say about post-sales

Curated quotes about customer outcomes, retention, renewals.

"Our focus on operational excellence, while ensuring we delight our customers and forge stronger relationships... is bearing fruit."
Steve Silvestro, CEO (CEO Opening Remarks)
"the vast majority of our business comes from renewals."
Ed Stelmakh, Chief Financial and Strategic Officer (Q&A)
"We are seeing a good growth in the mid-tier segment... we're able to provide capabilities that can... replace a lot of the stuff that they can't afford to do internally"
Steve Silvestro, CEO (Q&A)

Competitive dynamics

Get notified when OptimizeRx next discloses

One email when OPRX's next quarterly NRR figure is verified. No spam, work email only, unsubscribe anytime.

We send roughly 1 email per quarter, only when verified data lands.

Embed this chart

Free to embed on your blog or board deck. Includes a small backlink to cust.co.

<iframe src="https://cust.co/companies/oprx/embed/" width="600" height="400" frameborder="0"></iframe>

Or grab the data: JSON API

Every disclosure

Period NRR GRR Source type Filing
FY2025-Q4 116.0% - earnings-call-transcript source ↗
FY-2025 116.0% - 10-K source ↗
FY2025-Q3 120.0% - 10-Q-mdna source ↗
FY2025-Q2 121.0% - 10-Q-mdna source ↗
FY2025-Q1 114.0% - earnings-call-transcript source ↗
FY2024-Q4 121.0% - earnings-call-transcript source ↗
FY-2024 121.0% - 10-K source ↗
FY2024-Q3 127.0% - 10-Q-mdna source ↗
FY2024-Q2 124.0% - 10-Q-mdna source ↗
FY2023-Q4 121.0% - earnings-call-transcript source ↗
FY2023-Q3 127.0% - earnings-call-transcript source ↗
Last verified disclosure: 2025-12-31 · Report an inaccuracy → · How we verify →

How does your NRR compare to OptimizeRx's?

Free calculator. We email a shareable percentile badge.